GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » GF Value

Cencora (Cencora) GF Value : $189.55 (As of May. 03, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Cencora GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-03), Cencora's share price is $224.74. Cencora's GF Value is $189.55. Therefore, Cencora's Price-to-GF-Value for today is 1.19.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Cencora is Modestly Overvalued.


Cencora  (NYSE:COR) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Cencora's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=224.74/189.55
=1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cencora GF Value Related Terms

Thank you for viewing the detailed overview of Cencora's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cencora (Cencora) Business Description

Traded in Other Exchanges
Address
1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Executives
Leslie E Donato officer: EVP & Chief Strategy Officer 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Elizabeth S Campbell officer: Executive Vice President 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Steven H Collis officer: President & CEO 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Lazarus Krikorian officer: Senior Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Silvana Battaglia officer: Executive Vice President 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc. 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Werner Baumann director 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler director C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Robert P. Mauch officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Redonda Miller director 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg director 460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406
John G. Chou officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087